Presence of Wuchereria bancrofti microfilaremia despite 7 years of annual ivermectin monotherapy mass drug administration for onchocerciasis control: a study in north-west Ethiopia
Identifieur interne : 001971 ( Main/Exploration ); précédent : 001970; suivant : 001972Presence of Wuchereria bancrofti microfilaremia despite 7 years of annual ivermectin monotherapy mass drug administration for onchocerciasis control: a study in north-west Ethiopia
Auteurs : Tekola Endeshaw [Éthiopie] ; Aseged Taye [Éthiopie] ; Zerihun Tadesse [Éthiopie] ; Moses N. Katabarwa [États-Unis] ; Oumer Shafi [Éthiopie] ; Tewodros Seid [Éthiopie] ; Frank O. Richards [États-Unis]Source :
- Pathogens and Global Health [ 2047-7724 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Antiparasitaires (administration et posologie), Antiparasitaires (usage thérapeutique), Calendrier d'administration des médicaments, Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique (), Filariose lymphatique (transmission), Filariose lymphatique (épidémiologie), Humains, Ivermectine (administration et posologie), Ivermectine (usage thérapeutique), Maladies endémiques (), Microfilaria (isolement et purification), Mâle, Onchocercose (), Prévalence, Répartition par sexe, Répartition par âge, Sujet âgé, Utilisation médicament (), Wuchereria bancrofti, Éthiopie (épidémiologie).
- MESH :
- administration et posologie : Antiparasitaires, Ivermectine.
- isolement et purification : Microfilaria.
- usage thérapeutique : Antiparasitaires, Filariose lymphatique, Ivermectine.
- épidémiologie : Filariose lymphatique, Éthiopie.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Calendrier d'administration des médicaments, Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique, Humains, Maladies endémiques, Mâle, Onchocercose, Prévalence, Répartition par sexe, Répartition par âge, Sujet âgé, Utilisation médicament, Wuchereria bancrofti.
English descriptors
- KwdEn :
- Adolescent, Adult, Age Distribution, Aged, Animals, Antiparasitic Agents (administration & dosage), Antiparasitic Agents (therapeutic use), Child, Child, Preschool, Drug Administration Schedule, Drug Utilization (statistics & numerical data), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Elephantiasis, Filarial (transmission), Endemic Diseases (prevention & control), Ethiopia (epidemiology), Female, Humans, Ivermectin (administration & dosage), Ivermectin (therapeutic use), Male, Microfilariae (isolation & purification), Middle Aged, Onchocerciasis (prevention & control), Prevalence, Sex Distribution, Wuchereria bancrofti.
- MESH :
- chemical , administration & dosage : Antiparasitic Agents, Ivermectin.
- chemical , therapeutic use : Antiparasitic Agents, Ivermectin.
- epidemiology : Elephantiasis, Filarial, Ethiopia.
- isolation & purification : Microfilariae.
- prevention & control : Elephantiasis, Filarial, Endemic Diseases, Onchocerciasis.
- statistics & numerical data : Drug Utilization.
- transmission : Elephantiasis, Filarial.
- Adolescent, Adult, Age Distribution, Aged, Animals, Child, Child, Preschool, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prevalence, Sex Distribution, Wuchereria bancrofti.
Abstract
There is considerable interest in determining whether mass drug administration (MDA) with ivermectin for onchocerciasis control will eliminate coendemic lymphatic filariasis (LF). The objective of this study was to determine the prevalence of LF microfilaremia in onchocerciasis endemic districts that had received 7 years of MDA with ivermectin.
Three villages with a 2010 LF circulating antigenaemia prevalence (determined in a mapping exercise using immunochromatography tests) ranging from 23 to 56% were surveyed for the presence of
The mean mf prevalence was 4.7% (village range 1.1–11.0%). The mean mf density was 9.8 mf/60 μl (village range 9–13.1) among the positive individuals. Children in the 2–4-year-old and 5–9-year-old age groups were infected suggesting transmission occurred during the MDA period. A village level review of MDA treatment coverage records showed an average total population coverage of 66.4% over a 7-year period, but with a considerable range of annual coverage (43.0–89.9%). In addition, village level treatment coverage data were missing from the village with the highest mf prevalence (11%) for 2 of the 7 years.
7 years of annual mass treatment with ivermectin monotherapy for onchocerciasis did not interrupt LF transmission. In expanding the onchocerciasis ivermectin MDA programme to include LF, albendazole should be added and treatment coverage improved.
Url:
DOI: 10.1080/20477724.2015.1103501
PubMed: 26878935
PubMed Central: 4768627
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000696
- to stream Pmc, to step Curation: 000696
- to stream Pmc, to step Checkpoint: 000F65
- to stream PubMed, to step Corpus: 000A00
- to stream PubMed, to step Curation: 000A00
- to stream PubMed, to step Checkpoint: 000A00
- to stream Ncbi, to step Merge: 007E86
- to stream Ncbi, to step Curation: 007E86
- to stream Ncbi, to step Checkpoint: 007E86
- to stream Main, to step Merge: 001974
- to stream Main, to step Curation: 001971
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Presence of <italic>Wuchereria bancrofti</italic> microfilaremia despite 7 years of annual ivermectin monotherapy mass drug administration for onchocerciasis control: a study in north-west Ethiopia</title><author><name sortKey="Endeshaw, Tekola" sort="Endeshaw, Tekola" uniqKey="Endeshaw T" first="Tekola" last="Endeshaw">Tekola Endeshaw</name><affiliation wicri:level="1"><nlm:aff id="af1">The Carter Center, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>The Carter Center, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Taye, Aseged" sort="Taye, Aseged" uniqKey="Taye A" first="Aseged" last="Taye">Aseged Taye</name><affiliation wicri:level="1"><nlm:aff id="af1">The Carter Center, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>The Carter Center, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Tadesse, Zerihun" sort="Tadesse, Zerihun" uniqKey="Tadesse Z" first="Zerihun" last="Tadesse">Zerihun Tadesse</name><affiliation wicri:level="1"><nlm:aff id="af1">The Carter Center, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>The Carter Center, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Katabarwa, Moses N" sort="Katabarwa, Moses N" uniqKey="Katabarwa M" first="Moses N." last="Katabarwa">Moses N. Katabarwa</name><affiliation wicri:level="1"><nlm:aff id="af2">Department-Health Programs, The Carter Center, Atlanta, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department-Health Programs, The Carter Center, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Shafi, Oumer" sort="Shafi, Oumer" uniqKey="Shafi O" first="Oumer" last="Shafi">Oumer Shafi</name><affiliation wicri:level="1"><nlm:aff id="af3">National Disease Contro, The Federal Ministry of Health, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>National Disease Contro, The Federal Ministry of Health, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Seid, Tewodros" sort="Seid, Tewodros" uniqKey="Seid T" first="Tewodros" last="Seid">Tewodros Seid</name><affiliation wicri:level="1"><nlm:aff id="af1">The Carter Center, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>The Carter Center, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Richards, Frank O" sort="Richards, Frank O" uniqKey="Richards F" first="Frank O." last="Richards">Frank O. Richards</name><affiliation wicri:level="1"><nlm:aff id="af2">Department-Health Programs, The Carter Center, Atlanta, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department-Health Programs, The Carter Center, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26878935</idno><idno type="pmc">4768627</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768627</idno><idno type="RBID">PMC:4768627</idno><idno type="doi">10.1080/20477724.2015.1103501</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000696</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000696</idno><idno type="wicri:Area/Pmc/Curation">000696</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000696</idno><idno type="wicri:Area/Pmc/Checkpoint">000F65</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000F65</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000A00</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A00</idno><idno type="wicri:Area/PubMed/Curation">000A00</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A00</idno><idno type="wicri:Area/PubMed/Checkpoint">000A00</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A00</idno><idno type="wicri:Area/Ncbi/Merge">007E86</idno><idno type="wicri:Area/Ncbi/Curation">007E86</idno><idno type="wicri:Area/Ncbi/Checkpoint">007E86</idno><idno type="wicri:Area/Main/Merge">001974</idno><idno type="wicri:Area/Main/Curation">001971</idno><idno type="wicri:Area/Main/Exploration">001971</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Presence of <italic>Wuchereria bancrofti</italic> microfilaremia despite 7 years of annual ivermectin monotherapy mass drug administration for onchocerciasis control: a study in north-west Ethiopia</title><author><name sortKey="Endeshaw, Tekola" sort="Endeshaw, Tekola" uniqKey="Endeshaw T" first="Tekola" last="Endeshaw">Tekola Endeshaw</name><affiliation wicri:level="1"><nlm:aff id="af1">The Carter Center, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>The Carter Center, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Taye, Aseged" sort="Taye, Aseged" uniqKey="Taye A" first="Aseged" last="Taye">Aseged Taye</name><affiliation wicri:level="1"><nlm:aff id="af1">The Carter Center, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>The Carter Center, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Tadesse, Zerihun" sort="Tadesse, Zerihun" uniqKey="Tadesse Z" first="Zerihun" last="Tadesse">Zerihun Tadesse</name><affiliation wicri:level="1"><nlm:aff id="af1">The Carter Center, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>The Carter Center, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Katabarwa, Moses N" sort="Katabarwa, Moses N" uniqKey="Katabarwa M" first="Moses N." last="Katabarwa">Moses N. Katabarwa</name><affiliation wicri:level="1"><nlm:aff id="af2">Department-Health Programs, The Carter Center, Atlanta, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department-Health Programs, The Carter Center, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Shafi, Oumer" sort="Shafi, Oumer" uniqKey="Shafi O" first="Oumer" last="Shafi">Oumer Shafi</name><affiliation wicri:level="1"><nlm:aff id="af3">National Disease Contro, The Federal Ministry of Health, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>National Disease Contro, The Federal Ministry of Health, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Seid, Tewodros" sort="Seid, Tewodros" uniqKey="Seid T" first="Tewodros" last="Seid">Tewodros Seid</name><affiliation wicri:level="1"><nlm:aff id="af1">The Carter Center, Addis Ababa, Ethiopia</nlm:aff><country xml:lang="fr">Éthiopie</country><wicri:regionArea>The Carter Center, Addis Ababa</wicri:regionArea><wicri:noRegion>Addis Ababa</wicri:noRegion></affiliation></author><author><name sortKey="Richards, Frank O" sort="Richards, Frank O" uniqKey="Richards F" first="Frank O." last="Richards">Frank O. Richards</name><affiliation wicri:level="1"><nlm:aff id="af2">Department-Health Programs, The Carter Center, Atlanta, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department-Health Programs, The Carter Center, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author></analytic><series><title level="j">Pathogens and Global Health</title><idno type="ISSN">2047-7724</idno><idno type="eISSN">2047-7732</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Distribution</term><term>Aged</term><term>Animals</term><term>Antiparasitic Agents (administration & dosage)</term><term>Antiparasitic Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Drug Administration Schedule</term><term>Drug Utilization (statistics & numerical data)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Elephantiasis, Filarial (transmission)</term><term>Endemic Diseases (prevention & control)</term><term>Ethiopia (epidemiology)</term><term>Female</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (therapeutic use)</term><term>Male</term><term>Microfilariae (isolation & purification)</term><term>Middle Aged</term><term>Onchocerciasis (prevention & control)</term><term>Prevalence</term><term>Sex Distribution</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Antiparasitaires (administration et posologie)</term><term>Antiparasitaires (usage thérapeutique)</term><term>Calendrier d'administration des médicaments</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (transmission)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (usage thérapeutique)</term><term>Maladies endémiques ()</term><term>Microfilaria (isolement et purification)</term><term>Mâle</term><term>Onchocercose ()</term><term>Prévalence</term><term>Répartition par sexe</term><term>Répartition par âge</term><term>Sujet âgé</term><term>Utilisation médicament ()</term><term>Wuchereria bancrofti</term><term>Éthiopie (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparasitic Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparasitic Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiparasitaires</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Ethiopia</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Microfilariae</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Microfilaria</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Endemic Diseases</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Drug Utilization</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiparasitaires</term><term>Filariose lymphatique</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Éthiopie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Distribution</term><term>Aged</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Sex Distribution</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Calendrier d'administration des médicaments</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique</term><term>Humains</term><term>Maladies endémiques</term><term>Mâle</term><term>Onchocercose</term><term>Prévalence</term><term>Répartition par sexe</term><term>Répartition par âge</term><term>Sujet âgé</term><term>Utilisation médicament</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>There is considerable interest in determining whether mass drug administration (MDA) with ivermectin for onchocerciasis control will eliminate coendemic lymphatic filariasis (LF). The objective of this study was to determine the prevalence of LF microfilaremia in onchocerciasis endemic districts that had received 7 years of MDA with ivermectin.</p></sec><sec><title>Method</title><p>Three villages with a 2010 LF circulating antigenaemia prevalence (determined in a mapping exercise using immunochromatography tests) ranging from 23 to 56% were surveyed for the presence of <italic>Wuchereria bancrofti</italic> microfilaria (mf) in 2012. These villages had been treated with ivermectin MDA for onchocerciasis with reported total population coverage of ≥65%. A total of 774 residents aged 2 years and above, of both genders, provided 60 μl nocturnal blood samples between 10 pm and 2 am. Standard thick smears were prepared and examined microscopically after Giemsa staining for the presence of <italic>W. bancrofti</italic> mf.</p></sec><sec><title>Results</title><p>The mean mf prevalence was 4.7% (village range 1.1–11.0%). The mean mf density was 9.8 mf/60 μl (village range 9–13.1) among the positive individuals. Children in the 2–4-year-old and 5–9-year-old age groups were infected suggesting transmission occurred during the MDA period. A village level review of MDA treatment coverage records showed an average total population coverage of 66.4% over a 7-year period, but with a considerable range of annual coverage (43.0–89.9%). In addition, village level treatment coverage data were missing from the village with the highest mf prevalence (11%) for 2 of the 7 years.</p></sec><sec><title>Conclusion</title><p>7 years of annual mass treatment with ivermectin monotherapy for onchocerciasis did not interrupt LF transmission. In expanding the onchocerciasis ivermectin MDA programme to include LF, albendazole should be added and treatment coverage improved.</p></sec></div></front></TEI><affiliations><list><country><li>États-Unis</li><li>Éthiopie</li></country></list><tree><country name="Éthiopie"><noRegion><name sortKey="Endeshaw, Tekola" sort="Endeshaw, Tekola" uniqKey="Endeshaw T" first="Tekola" last="Endeshaw">Tekola Endeshaw</name></noRegion><name sortKey="Seid, Tewodros" sort="Seid, Tewodros" uniqKey="Seid T" first="Tewodros" last="Seid">Tewodros Seid</name><name sortKey="Shafi, Oumer" sort="Shafi, Oumer" uniqKey="Shafi O" first="Oumer" last="Shafi">Oumer Shafi</name><name sortKey="Tadesse, Zerihun" sort="Tadesse, Zerihun" uniqKey="Tadesse Z" first="Zerihun" last="Tadesse">Zerihun Tadesse</name><name sortKey="Taye, Aseged" sort="Taye, Aseged" uniqKey="Taye A" first="Aseged" last="Taye">Aseged Taye</name></country><country name="États-Unis"><noRegion><name sortKey="Katabarwa, Moses N" sort="Katabarwa, Moses N" uniqKey="Katabarwa M" first="Moses N." last="Katabarwa">Moses N. Katabarwa</name></noRegion><name sortKey="Richards, Frank O" sort="Richards, Frank O" uniqKey="Richards F" first="Frank O." last="Richards">Frank O. Richards</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001971 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001971 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4768627
|texte= Presence of Wuchereria bancrofti microfilaremia despite 7 years of annual ivermectin monotherapy mass drug administration for onchocerciasis control: a study in north-west Ethiopia
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26878935" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |